Oricell Therapeutics
Oricell explicitly lists OriV508, a CD19/BCMA in vivo CAR-T program, as IIT ongoing, and OriV118 targeting GPRC5D/BCMA. The pipeline does not establish the delivery platform or OriV118’s current stage. Its ex vivo OriCAR-017 data must be kept separate.
Corporate information
- Company entity
- Oricell Therapeutics
- Headquarters / principal office
- ShanghaiSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivatePre-IPO financing, cumulative closing in April 2026 ↗
- Official corporate reference
- https://www.oricell.com/en/product/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-04-10 · Cumulative pre-IPO round closing · More than $110 million ↗
April announcement uses cumulative round-closing scope. Do not add the January $70 million again or treat this as total lifetime financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Oricell explicitly lists OriV508, a CD19/BCMA in vivo CAR-T program, as IIT ongoing, and OriV118 targeting GPRC5D/BCMA. The pipeline does not establish the delivery platform or OriV118’s current stage. Its ex vivo OriCAR-017 data must be kept separate.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Our Pipeline
- Oricell — About Us
- Oricell — cumulative pre-IPO financing closing
- Company-managed LinkedIn profile — self-reported location